Severe Pancytopenia Induced by Valproic Acid.

Area of Science:

• Pediatric Neurology
• Hematology
• Pharmacology

Background:

• Valproic acid is a primary antiepileptic drug for pediatric epilepsy.
• Hepatotoxicity is a known side effect, but bone marrow suppression is rare.
• Limited evidence exists for managing valproic acid-induced hematologic toxicity.

Observation:

• A 10-year-old male patient developed bone marrow suppression.
• The complication occurred with high-dose valproic acid therapy.
• Valproic acid levels exceeded 125 mcg/mL.

Findings:

• The case highlights a rare but serious adverse effect of valproic acid.
• Bone marrow suppression presents a significant hematologic toxicity.
• This complication is associated with elevated valproic acid serum concentrations.

Implications:

• Increased vigilance for hematologic toxicity in pediatric epilepsy patients on valproic acid is warranted.
• Further studies are needed to establish clear management guidelines for this rare complication.
• Understanding the risk factors and mechanisms can improve patient safety and treatment outcomes.